Status:
COMPLETED
Macrophages, GM-CSF and MARS Proteinosis
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborating Sponsors:
URC-CIC Paris Descartes Necker Cochin
Conditions:
Pulmonary Alveolar Proteinosis (PAP)
MARS
Eligibility:
All Genders
Up to 17 years
Brief Summary
Mutations in the MARS gene encoding methionyl-tRNA synthetase are responsible for a genetic form of alveolar proteinosis (PAP), but the pathophysiological mechanisms of the respiratory phenotype are n...
Detailed Description
Pulmonary alveolar proteinosis (PAP) is a rare respiratory disease characterized by the accumulation of lipoproteinaceous material within the pulmonary alveoli, resulting in the majority of cases from...
Eligibility Criteria
Inclusion
- Minors from 0 to 17 years hospitalized for their care at Necker Enfants Malades hospital and for whom a blood sample and a bronchoscopy with bronchoalveolar lavage must be performed as part of their care
- Information and consent of the holders of parental authority and the patient
Exclusion
- \- Refusal of holders of parental authority or patient
Key Trial Info
Start Date :
June 7 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 6 2021
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04811274
Start Date
June 7 2021
End Date
November 6 2021
Last Update
September 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Necker-Enfants Malades
Paris, France, 75015